// App-Quantinova.ai

TPS5096 : A phase I/II study of bintrafusp alfa and NHS-IL12 in combination with docetaxel in adults with metastatic castration sensitive (mCSPC) and castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Mohammad O. Atiq

Principal Investigators

  • Marijo Bilusic

  • Fatima Karzai

  • Lisa M. Cordes

  • Julius Strauss

  • Houssein Abdul Sater

  • Jason Redman

  • Charalampos S. Floudas

  • James W. Hodge

  • Sofia Gameiro

  • William Douglas Figg

  • Jeffrey Schlom

  • William L. Dahut

  • James L. Gulley

  • Ravi Amrit Madan

Medical Centers

  • National Cancer Institute, Bethesda, MD

  • Genitourinary Malignancies Branch, CCR, NCI, NIH, Bethesda, MD

  • Laboratory of Tumor Immunology and Biology, CCR, NCI, NIH, Bethesda, MD

  • Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD

  • Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, MD

  • Clinical Pharmacology Program, National Institutes of Health, Bethesda, MD

  • Gastrointestinal Malignancies Section, Center for Cancer Research, National Cancer Institute at the National Institutes of Health, Bethesda, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

  • Brain metastasis

  • Prostate cancer

  • Solid malignancies

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • Docetaxel

  • NHS-IL12

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • NCT04633252

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved